ARS Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SPRY Nasdaq 2836 ars-pharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ARS Pharmaceuticals, Inc.

Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies - Jun 4th, 2026 6:00 am
ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - May 16th, 2026 6:30 am
ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... - May 15th, 2026 5:01 pm
Sector Update: Healthcare Stocks Decline Late Afternoon - May 15th, 2026 1:52 pm
ARS Pharmaceuticals Q1 Earnings Call Highlights - May 15th, 2026 10:09 am
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates - May 15th, 2026 5:10 am
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update - May 15th, 2026 4:00 am
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates - May 14th, 2026 3:30 pm
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President - May 13th, 2026 6:00 am
Cronos Group (CRON) Q1 Earnings Meet Estimates - May 11th, 2026 6:45 am
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates - May 7th, 2026 6:50 am
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results - May 7th, 2026 6:00 am
Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to Decline - May 6th, 2026 8:00 am
How The ARS Pharmaceuticals (SPRY) Narrative Is Shifting With Fresh Analyst Models And Approvals - May 2nd, 2026 3:13 pm
ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock? - Apr 23rd, 2026 6:41 am
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver - Apr 17th, 2026 7:58 am
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - Apr 15th, 2026 4:05 am
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label - Mar 27th, 2026 6:00 am
ARS Pharmaceuticals Q4 Earnings Call Highlights - Mar 9th, 2026 3:18 pm
ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ... - Mar 9th, 2026 1:01 pm